Stockreport

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease [Yahoo! Finance]

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF Dalzanemdor (SAGE-718) was generally well-tolerated and there were no new safety signals observed - Topline data readouts from the Phase 2 studies in Huntington's dis [Read more]